{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:27:46Z","timestamp":1762867666460,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.endien.2020.10.007","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T17:20:06Z","timestamp":1623518406000},"page":"196-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recommendations on the pathological report of pituitary tumors. A consensus of experts of the Spanish Society of Endocrinology and Nutrition and the Spanish Society of Pathology"],"prefix":"10.1016","volume":"68","author":[{"given":"Antonio","family":"Pic\u00f3","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Aranda-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Sesmilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d3scar","family":"Toldos-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Jap\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal M.","family":"Luque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manel","family":"Puig-Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.endien.2020.10.007_bib0005","doi-asserted-by":"crossref","first-page":"C5","DOI":"10.1530\/ERC-17-0004","article-title":"From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal","volume":"24","author":"Asa","year":"2017","journal-title":"Endocr Relat Cancer"},{"year":"2017","author":"Lloyd","series-title":"WHO classification of tumours of endocrine organs","key":"10.1016\/j.endien.2020.10.007_bib0010"},{"key":"10.1016\/j.endien.2020.10.007_bib0015","series-title":"Atlas of Tumor Pathology (AFIP) third series","article-title":"Tumors of the Pituitary Gland","author":"Asa","year":"1998"},{"issue":"8","key":"10.1016\/j.endien.2020.10.007_bib0020","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.5858\/2008-132-1231-PPPWDT","article-title":"Practical pituitary pathology: what does the pathologist need to know?","volume":"132","author":"Asa","year":"2008","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.endien.2020.10.007_bib0025","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1530\/eje.1.02326","article-title":"Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry","volume":"156","author":"Saeger","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.endien.2020.10.007_bib0030","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1530\/EJE-14-0144","article-title":"The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011","volume":"171","author":"Tjornstrand","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"10.1016\/j.endien.2020.10.007_bib0035","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1055\/s-0043-115645","article-title":"Prevalence, clinical features, and natural history of incidental clinically non-functioning pituitary adenomas","volume":"49","author":"Iglesias","year":"2017","journal-title":"Horm Metab Res"},{"issue":"6","key":"10.1016\/j.endien.2020.10.007_bib0040","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s11102-019-00988-2","article-title":"A tale of pituitary adenomas: to NET or not to NET : Pituitary Society position statement","volume":"22","author":"Ho","year":"2019","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.endien.2020.10.007_bib0045","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s11102-019-01015-0","article-title":"Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution","volume":"23","author":"Asa","year":"2020","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.endien.2020.10.007_bib0050","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s12022-015-9398-z","article-title":"The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas","volume":"26","author":"Nishioka","year":"2015","journal-title":"Endocr Pathol"},{"issue":"7","key":"10.1016\/j.endien.2020.10.007_bib0055","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1210\/jc.2018-00688","article-title":"Clinical and pathological aspects of silent pituitary adenomas","volume":"104","author":"Drummond","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.endien.2020.10.007_bib0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/modpathol.2015.151","article-title":"Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas","volume":"29","author":"Mete","year":"2016","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.endien.2020.10.007_bib0065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","article-title":"A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up","volume":"126","author":"Trouillas","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1016\/j.endien.2020.10.007_bib0070","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1530\/EJE-18-0749","article-title":"Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre","volume":"180","author":"Asioli","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.endien.2020.10.007_bib0075","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020514","article-title":"How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020","volume":"12","author":"Trouillas","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.endien.2020.10.007_bib0080","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00428-019-02655-0","article-title":"A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal","volume":"475","author":"Villa","year":"2019","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1016\/j.endien.2020.10.007_bib0085","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s12022-014-9342-7","article-title":"Letter to the editor","volume":"26","author":"Kovacs","year":"2015","journal-title":"Endocr Pathol"},{"issue":"5","key":"10.1016\/j.endien.2020.10.007_bib0090","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1530\/EJE-15-0189","article-title":"The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study","volume":"173","author":"Agustsson","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.endien.2020.10.007_bib0095","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1210\/jc.2014-2362","article-title":"Clinical review: functioning gonadotroph adenomas","volume":"99","author":"Ntali","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2020.10.007_bib0100","first-page":"123","article-title":"Recent clinical and pathophysiological advances in non-functioning pituitary adenomas","volume":"71 Suppl 2","author":"Korbonits","year":"2009","journal-title":"Horm Res"},{"issue":"3","key":"10.1016\/j.endien.2020.10.007_bib0105","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11060-014-1425-2","article-title":"Silent (clinically nonfunctioning) pituitary adenomas","volume":"117","author":"Mayson","year":"2014","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1016\/j.endien.2020.10.007_bib0110","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11102-008-0085-7","article-title":"Modification of hormonal secretion in clinically silent pituitary adenomas","volume":"12","author":"Daems","year":"2009","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.endien.2020.10.007_bib0115","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12020-016-1028-0","article-title":"The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1\/3","volume":"56","author":"Righi","year":"2017","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.endien.2020.10.007_bib0120","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1385\/EP:17:2:191","article-title":"Cushing\u2019s disease arising from a clinically nonfunctioning pituitary adenoma","volume":"17","author":"Salgado","year":"2006","journal-title":"Endocr Pathol"},{"issue":"4","key":"10.1016\/j.endien.2020.10.007_bib0125","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41379-018-0167-7","article-title":"GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors","volume":"32","author":"Mete","year":"2019","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.endien.2020.10.007_bib0130","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121990","article-title":"How valuable is the RT-qPCR of pituitary-specific transcription factors for identifying pituitary neuroendocrine tumor subtypes according to the new WHO 2017 criteria?","volume":"11","author":"Torregrosa-Quesada","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.endien.2020.10.007_bib0135","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2265.2008.03514.x","article-title":"Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience","volume":"71","author":"Erickson","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.endien.2020.10.007_bib0140","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.endien.2020.10.007_bib0145","series-title":"WHO classification of tumours of endocrine organs","first-page":"37","article-title":"Null cell adenoma","author":"Nishioka","year":"2017"},{"issue":"7","key":"10.1016\/j.endien.2020.10.007_bib0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180039","article-title":"Contribution of molecular analysis to the typification of the non-functioning pituitary adenomas","volume":"12","author":"Sanchez-Tejada","year":"2017","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.endien.2020.10.007_bib0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198877","article-title":"Is it time to consider the expression of specific-pituitary hormone genes when typifying pituitary tumours?","volume":"13","author":"Garcia-Martinez","year":"2018","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.endien.2020.10.007_bib0160","first-page":"565","article-title":"Production of alpha-subunit of glycoprotein hormones by pituitary somatotroph adenomas in vitro","volume":"129","author":"Kontogeorgos","year":"1993","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"2","key":"10.1016\/j.endien.2020.10.007_bib0165","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF03401473","article-title":"The gonadotroph origin of null cell adenomas","volume":"15","author":"Kontogeorgos","year":"2016","journal-title":"Hormones (Athens)"},{"issue":"6","key":"10.1016\/j.endien.2020.10.007_bib0170","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/s41379-018-0016-8","article-title":"Epidemiology and biomarker profile of pituitary adenohypophysial tumors","volume":"31","author":"Mete","year":"2018","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.endien.2020.10.007_bib0175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10014-017-0307-7","article-title":"New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors","volume":"35","author":"Nishioka","year":"2018","journal-title":"Brain Tumor Pathol"},{"issue":"1","key":"10.1016\/j.endien.2020.10.007_bib0180","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12022-014-9347-2","article-title":"Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics","volume":"26","author":"Balogun","year":"2015","journal-title":"Endocr Pathol"},{"issue":"5","key":"10.1016\/j.endien.2020.10.007_bib0185","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11102-019-00981-9","article-title":"Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers","volume":"22","author":"Almeida","year":"2019","journal-title":"Pituitary"},{"key":"10.1016\/j.endien.2020.10.007_bib0190","series-title":"Libro Blanco de la Anatom\u00eda Patol\u00f3gica en Espa\u00f1a [Internet]. Madrid: Sociedad Espa\u00f1ola de Anatom\u00eda Patol\u00f3gica - International Academy of Pathology(SEAP-IAP); [666]","article-title":"Patolog\u00eda de la hip\u00f3fisis","author":"Toldos-Gonz\u00e1lez","year":"2017"},{"issue":"3","key":"10.1016\/j.endien.2020.10.007_bib0195","doi-asserted-by":"crossref","first-page":"356","DOI":"10.5858\/arpa.2014-0020-OA","article-title":"An algorithmic approach to sellar region masses","volume":"139","author":"Kleinschmidt-DeMasters","year":"2015","journal-title":"Arch Pathol Lab Med"},{"issue":"12","key":"10.1016\/j.endien.2020.10.007_bib0200","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.5858\/2005-129-1635-ICCPAF","article-title":"Intraoperative consultation, cytologic preparations, and frozen section in the central nervous system","volume":"129","author":"Powell","year":"2005","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.endien.2020.10.007_bib0205","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5858\/arpa.2016-0082-OA","article-title":"Steroidogenic Factor 1, Pit-1, and adrenocorticotropic hormone: a rational starting place for the immunohistochemical characterization of pituitary adenoma","volume":"141","author":"McDonald","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.endien.2020.10.007_bib0210","article-title":"Invited Review: pathology of pituitary neuroendocrine tumours: present status, modern diagnostic approach, controversies and future perspectives from a neuropathological and clinical standpoint","author":"Manojlovic-Gacic","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.endien.2020.10.007_bib0215","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-18-0565","article-title":"Molecular profiling for acromegaly treatment: a validation study","author":"Puig-Domingo","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"10.1016\/j.endien.2020.10.007_bib0220","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.1210\/jc.2005-0998","article-title":"The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly","volume":"90","author":"Bhayana","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.endien.2020.10.007_bib0225","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00006123-199601000-00024","article-title":"Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody","volume":"38","author":"Thapar","year":"1996","journal-title":"Neurosurgery."},{"issue":"2","key":"10.1016\/j.endien.2020.10.007_bib0230","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s12022-014-9322-y","article-title":"In search of a prognostic classification of endocrine pituitary tumors","volume":"25","author":"Trouillas","year":"2014","journal-title":"Endocr Pathol"},{"issue":"1","key":"10.1016\/j.endien.2020.10.007_bib0235","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"4","key":"10.1016\/j.endien.2020.10.007_bib0240","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00401-017-1769-8","article-title":"The 2017 World Health Organization classification of tumors of the pituitary gland: a summary","volume":"134","author":"Lopes","year":"2017","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1016\/j.endien.2020.10.007_bib0245","doi-asserted-by":"crossref","first-page":"129","DOI":"10.23736\/S0391-1977.18.02933-4","article-title":"Pathological markers of somatotroph pituitary neuroendocrine tumors predicting the response to medical treatment","volume":"44","author":"Trouillas","year":"2019","journal-title":"Minerva Endocrinol"},{"issue":"3","key":"10.1016\/j.endien.2020.10.007_bib0250","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/jcmm.13440","article-title":"Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly","volume":"22","author":"Venegas-Moreno","year":"2018","journal-title":"J Cell Mol Med"},{"issue":"4","key":"10.1016\/j.endien.2020.10.007_bib0255","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1158\/1078-0432.CCR-19-2154","article-title":"A Somatostatin Receptor Subtype-3 (SST3) peptide agonist shows antitumor effects in experimental models of nonfunctioning pituitary tumors","volume":"26","author":"Vazquez-Borrego","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.endien.2020.10.007_bib0260","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1111\/jcmm.13851","article-title":"E-cadherin expression is associated with somatostatin analogue response in acromegaly","volume":"23","author":"Venegas-Moreno","year":"2019","journal-title":"J Cell Mol Med"},{"issue":"3","key":"10.1016\/j.endien.2020.10.007_bib0265","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz211","article-title":"Efficacy of temozolomide therapy in patients with aggressive pituitary adenomas and carcinomas\u2014A German survey","volume":"105","author":"Elbelt","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.endien.2020.10.007_bib0270","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1210\/jc.2012-2924","article-title":"DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors","volume":"98","author":"Hirohata","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.endien.2020.10.007_bib0275","doi-asserted-by":"crossref","first-page":"640","DOI":"10.5858\/2010-0470-SAR1.1","article-title":"Protocol for the examination of specimens from patients with primary pituitary tumors","volume":"135","author":"Nose","year":"2011","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"10.1016\/j.endien.2020.10.007_bib0280","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","article-title":"Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): a Pituitary Society statement","volume":"20","author":"Casanueva","year":"2017","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.endien.2020.10.007_bib0285","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1210\/jc.2007-2272","article-title":"Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment","volume":"93","author":"Fougner","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2020.10.007_bib0290","series-title":"GeneReviews((R))","article-title":"AIP familial isolated pituitary adenomas","author":"Korbonits","year":"1993"},{"issue":"2","key":"10.1016\/j.endien.2020.10.007_bib0295","doi-asserted-by":"crossref","first-page":"109","DOI":"10.23736\/S0391-1977.19.02970-5","article-title":"Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors","volume":"44","author":"Fuentes-Fayos","year":"2019","journal-title":"Minerva Endocrinol"},{"issue":"3","key":"10.1016\/j.endien.2020.10.007_bib0300","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/17446651.2017.1312341","article-title":"Selective molecular biomarkers to predict biologic behavior in pituitary tumors","volume":"12","author":"Sav","year":"2017","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.endien.2020.10.007_bib0305","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101439","article-title":"Splicing machinery is dysregulated in pituitary neuroendocrine tumors and is associated with aggressiveness features","volume":"11","author":"V\u00e1zquez-Borrego","year":"2019","journal-title":"Cancers (Basel)"}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018021000408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018021000408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:15:08Z","timestamp":1762866908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530018021000408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2530018021000408"],"URL":"https:\/\/doi.org\/10.1016\/j.endien.2020.10.007","relation":{},"ISSN":["2530-0180"],"issn-type":[{"type":"print","value":"2530-0180"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations on the pathological report of pituitary tumors. A consensus of experts of the Spanish Society of Endocrinology and Nutrition and the Spanish Society of Pathology","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endien.2020.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.endinu.2020.10.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 SEEN and SED. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}